Literature DB >> 17401504

HLA-DRB1 alleles in juvenile-onset systemic lupus erythematosus: renal histologic class correlations.

B L Liphaus1, M H B Kiss, A C Goldberg.   

Abstract

Human leukocyte antigens (HLA) DRB1*03 and DRB1*02 have been associated with systemic lupus erythematosus (SLE) in Caucasians and black populations. It has been observed that certain HLA alleles show stronger associations with SLE autoantibodies and clinical subsets, although they have rarely been associated with lupus renal histologic class. In the present study, HLA-DRB1 allele correlations with clinical features, autoantibodies and renal histologic class were analyzed in a cohort of racially mixed Brazilian patients with juvenile-onset SLE. HLA-DRB1 typing was carried out by polymerase chain reaction amplification with sequence-specific primers using genomic DNA from 55 children and adolescents fulfilling at least four of the American College of Rheumatology criteria for SLE. Significance was determined by the chi-square test applied to 2 x 2 tables. The HLA-DRB1*15 allele was most frequent in patients with renal, musculoskeletal, cutaneous, hematologic, cardiac, and neuropsychiatric involvement, as well as in patients positive for anti-dsDNA, anti-Sm, anti-U1-RNP, and anti-SSA/Ro antibodies, although an association between HLA alleles and SLE clinical features and autoantibodies could not be observed. The HLA-DRB1*17, HLA-DRB1*10, HLA-DRB1*15, and HLA-DRB1*07 alleles were significantly higher in patients with renal histologic class I, class IIA, class IIB, and class V, respectively. The present results suggest that the contribution of HLA- DRB1 alleles to juvenile-onset SLE could not be related to clinical or serological subsets of the disease, but it may be related to renal histologic classes, especially class I, class II A, class II B, and class V. The latter correlations have not been observed in literature.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17401504     DOI: 10.1590/s0100-879x2007000400019

Source DB:  PubMed          Journal:  Braz J Med Biol Res        ISSN: 0100-879X            Impact factor:   2.590


  6 in total

Review 1.  The role of apoptosis proteins and complement components in the etiopathogenesis of systemic lupus erythematosus.

Authors:  Bernadete L Liphaus; Maria Helena Bittencourt Kiss
Journal:  Clinics (Sao Paulo)       Date:  2010-03       Impact factor: 2.365

2.  Relation between HLA typing and clinical presentations in Systemic Lupus Erythematosus patients in Al-Qassim region, Saudi Arabia.

Authors:  Walid Wadi; Noor Eldeen A M Elhefny; Essam H Mahgoub; Adel Almogren; Khaled D Hamam; Hamad A Al-Hamed; Gasim I Gasim
Journal:  Int J Health Sci (Qassim)       Date:  2014-04

Review 3.  Systemic Lupus Erythematosus in Children and Young People.

Authors:  A Charras; E Smith; C M Hedrich
Journal:  Curr Rheumatol Rep       Date:  2021-02-10       Impact factor: 4.592

4.  Deletions in VANGL1 are a risk factor for antibody-mediated kidney disease.

Authors:  Simon H Jiang; Sevcan Mercan; Ilenia Papa; Max Moldovan; Giles D Walters; Mark Koina; Mitali Fadia; Maurice Stanley; Tom Lea-Henry; Amelia Cook; Julia Ellyard; Brendan McMorran; Madhivanan Sundaram; Russell Thomson; Pablo F Canete; Wendy Hoy; Holly Hutton; Monika Srivastava; Kathryn McKeon; Iñigo de la Rúa Figueroa; Ricard Cervera; Raquel Faria; Sandra D'Alfonso; Mariele Gatto; Vicki Athanasopoulos; Matthew Field; John Mathews; Eun Cho; Thomas D Andrews; A Richard Kitching; Matthew C Cook; Marta Alarcon Riquelme; Melanie Bahlo; Carola G Vinuesa
Journal:  Cell Rep Med       Date:  2021-12-21

Review 5.  CD4+ Cytotoxic T Cells Involved in the Development of EBV-Associated Diseases.

Authors:  Manuel Ruiz-Pablos
Journal:  Pathogens       Date:  2022-07-25

6.  Autoantibody Profile of Egyptian Juvenile Systemic Lupus Erythematosus Patients and Its Association with Clinical Characteristics and Disease Activity.

Authors:  Mohammed Abd El Monem Teama; Marwa Adham El-Mohamdy; Fatma Abdellah Abdullah Mahmoud; Fatma Mohammed Badr
Journal:  Open Access Rheumatol       Date:  2021-07-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.